US 11,672,820 B2
Ophthalmic compositions with improved dessication protection and retention
James W. Davis, Falmouth, ME (US); Howard Allen Ketelson, Dallas, TX (US); Elaine E. Campbell, Shelton, CT (US); David L. Meadows, Colleyville, TX (US); and Rekha Rangarajan, Fort Worth, TX (US)
Assigned to Alcon Inc., Fribourg (CH)
Filed by Alcon Inc., Fribourg (CH)
Filed on May 19, 2022, as Appl. No. 17/664,143.
Application 17/664,143 is a continuation of application No. 17/060,343, filed on Oct. 1, 2020, granted, now 11,376,275.
Application 17/060,343 is a continuation of application No. 16/721,443, filed on Dec. 19, 2019, granted, now 10,828,320, issued on Nov. 10, 2020.
Application 16/721,443 is a continuation of application No. 15/421,513, filed on Feb. 1, 2017, abandoned.
Application 15/421,513 is a continuation of application No. 13/886,788, filed on May 3, 2013, abandoned.
Claims priority of provisional application 61/642,901, filed on May 4, 2012.
Prior Publication US 2022/0273699 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/736 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 47/32 (2006.01); A61K 31/728 (2006.01)
CPC A61K 31/736 (2013.01) [A61K 9/0048 (2013.01); A61K 31/728 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01)] 12 Claims
 
1. An ophthalmic composition comprising 0.1 to 0.2 w/v % hydroxylpropyl guar, 0.13 to 0.17 w/v % hyaluronic acid, 1.0 to 2.0 w/v % cis-diol and a pharmaceutically active compound, wherein the cis-diol is sorbitol and the pharmaceutically active compound is selected from the group consisting of a glaucoma therapeutic, a pain reliever, an anti-inflammatory medication, an anti-allergy medication, a post- surgical antihypertensive agent, a dry eye therapeutic, an anti-infective, and an anti-microbial, for the treatment of ophthalmic diseases.